MoleculeDx

Finding reliable signals for hepatocellular carcinoma (HCC) remains a challenge because biological differences among tumors can affect what appears in blood. An HCC screening test built around a single marker may not capture that variation. MoleculeDx approaches this question through cancer-associated fusion transcripts—RNA molecules that can be produced when parts of genes become joined through cancer-associated genomic rearrangements. Its research program evaluates multiple fusion-transcript signals in blood or serum and uses machine-learning models to combine measured molecular features. This approach is designed to support risk assessment while preserving an essential principle: a blood-based result is not a stand-alone diagnosis.  What Are Fusion Genes and Fusion Transcripts? Chromosomal rearrangements can generate recurrent fusion genes whose RNA products may be detected as fusion transcripts. A fusion gene describes the underlying genomic rearrangement joining genetic materi...